Fusion Pharmaceuticals (Nasdaq:FUSN) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

FUSN Aperçu des actions

A clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States.

A propos de l'entreprise

FUSN analyse fondamentale
Score flocon de neige
Évaluation	0/6
Croissance future	2/6
Performances passées	0/6
Santé financière	5/6
Dividendes	0/6

Récompenses

Les revenus devraient augmenter 67.75% par an

Analyse des risques

Cours de l'action très volatil au cours des 3 derniers mois

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

Les actionnaires ont été dilués au cours de l'année écoulée

N'a pas de revenus significatifs ( $2M )

Fusion Pharmaceuticals Inc. Concurrents

Deciphera Pharmaceuticals

NasdaqGS:DCPH

US$2.2b

Zai Lab

NasdaqGM:ZLAB

US$2.3b

Nurix Therapeutics

NasdaqGM:NRIX

US$1.5b

Veracyte

NasdaqGM:VCYT

US$2.6b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Fusion Pharmaceuticals
Historique des cours de bourse
Prix actuel de l'action	US$21.55
Plus haut sur 52 semaines	US$21.60
Plus bas sur 52 semaines	US$2.31
Bêta	-0.69
1Variation sur 1 mois	0.70%
Variation sur 3 mois	114.64%
Variation sur 1 an	332.73%
3Variation sur 3 ans	150.29%
Variation sur 5 ans	n/a
Évolution depuis l'introduction en bourse	26.76%

Nouvelles et mises à jour récentes

Recent updates

Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook

Mar 03

Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?

Jan 30

Fusion Pharmaceuticals initiated at buy at Truist on lead candidate for solid tumors

Sep 16

Fusion Pharma doses first patient in phase 1/2 study for solid tumors treatment

Aug 29

Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?

Aug 10

Fusion Pharmaceuticals GAAP EPS of -$0.44 beats by $0.09, revenue of $0.57M beats by $0.46M

Aug 09

Fusion Pharma wins FDA nod to start trials for solid tumor candidate

Jun 23

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Jan 16

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Aug 28

Fusion Pharma trades higher on early-stage data for cancer therapy

Jun 14

We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely

Apr 05

How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?

Mar 01

Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?

Jan 25

Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation

Dec 21

Fusion Pharmaceuticals EPS misses by $0.04

Nov 10

Fusion Pharma teams up with AstraZeneca in next-gen radiopharmaceuticals for cancer

Nov 02

Rendement pour les actionnaires

	FUSN	US Biotechs	US Marché
7D	0.4%	-2.9%	0.9%
1Y	332.7%	18.9%	32.3%

Rendement vs Industrie: FUSN a dépassé le secteur US Biotechs qui a rapporté 15.7 % au cours de l'année écoulée.

Rendement vs marché: FUSN a dépassé le marché US qui a rapporté 25.6 % au cours de l'année écoulée.

Volatilité des prix

Is FUSN's price volatile compared to industry and market?
FUSN volatility
FUSN Average Weekly Movement	28.5%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.2%

Cours de l'action stable: Le cours de l'action de FUSN a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de FUSN est passée de 18% à 29% au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2014	101	John Valliant	www.fusionpharma.com

Fusion Pharmaceuticals Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Fusion Pharmaceuticals se comparent-ils à sa capitalisation boursière ?
FUSN statistiques fondamentales
Capitalisation boursière	US$1.83b
Bénéfices(TTM)	-US$104.28m
Recettes(TTM)	US$2.04m

898.6x

Ratio P/S

-17.6x

Ratio P/E

Le site FUSN est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
FUSN compte de résultat (TTM)
Recettes	US$2.04m
Coût des recettes	US$75.54m
Marge brute	-US$73.50m
Autres dépenses	US$30.78m
Les revenus	-US$104.28m

Derniers bénéfices déclarés

Mar 31, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-1.23
Marge brute	-3,602.84%
Marge bénéficiaire nette	-5,111.57%
Ratio dettes/capitaux propres	20.5%

Quelles ont été les performances à long terme de FUSN?

Voir les performances historiques et les comparaisons

FUSN Aperçu des actions

Récompenses

Analyse des risques

Fusion Pharmaceuticals Inc. Concurrents

NasdaqGS:DCPH

US$2.2b

NasdaqGM:ZLAB

US$2.3b

NasdaqGM:NRIX

US$1.5b

NasdaqGM:VCYT

US$2.6b

Historique des prix et performances

Nouvelles et mises à jour récentes

Fusion Pharmaceuticals Files Form 15

Fusion Pharmaceuticals Inc.(NasdaqGS:FUSN) dropped from NASDAQ Biotechnology Index

Fusion Pharmaceuticals Inc. Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer

First quarter 2024 earnings released: US$0.40 loss per share (vs US$0.45 loss in 1Q 2023)

Third quarter 2023 earnings released: US$0.25 loss per share (vs US$0.55 loss in 3Q 2022)

AstraZeneca AB entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) for $1.8 billion.

Recent updates

Fusion Pharmaceuticals Files Form 15

Fusion Pharmaceuticals Inc.(NasdaqGS:FUSN) dropped from NASDAQ Biotechnology Index

Fusion Pharmaceuticals Inc. Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer

First quarter 2024 earnings released: US$0.40 loss per share (vs US$0.45 loss in 1Q 2023)

Third quarter 2023 earnings released: US$0.25 loss per share (vs US$0.55 loss in 3Q 2022)

AstraZeneca AB entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) for $1.8 billion.

Consensus EPS estimates fall by 11%

AstraZeneca AB entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) for $1.8 billion.

AstraZeneca AB entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) for $1.8 billion.

AstraZeneca PLC (LSE:AZN) entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) for $1.5 billion.

Price target increased by 34% to US$18.80

AstraZeneca PLC (LSE:AZN) entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) for $1.5 billion.

Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook

Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?

Price target increased by 7.5% to US$14.27

Consensus revenue estimates increase by 266%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fusion Pharmaceuticals Inc. Announces Board Changes

Fusion Pharmaceuticals Inc. Announces Presentation of Preclinical Data Supporting FPI-2068, A Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers

Consensus revenue estimates increase by 160%

New minor risk - Share price stability

Consensus revenue estimates increase by 304%

Consensus revenue estimates fall by 91%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Fusion Pharmaceuticals Inc. to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R

Consensus revenue estimates increase by 289%

New major risk - Shareholder dilution

Fusion Pharmaceuticals Inc. announced that it expects to receive $20 million in funding from Federated Hermes, Inc.

Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T

Fusion Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2023

Price target decreased to US$13.95

Fusion Pharmaceuticals Appoints Dmitri Bobilev as Chief Medical Officer

Fusion Pharmaceuticals initiated at buy at Truist on lead candidate for solid tumors

Fusion Pharmaceuticals Inc. Announces First Patient Dosed in Phase 1/2 Study of FPI-1966 in Patients with Advanced Solid Tumors Expressing FGFR3

Fusion Pharma doses first patient in phase 1/2 study for solid tumors treatment

Independent Director recently bought US$90k worth of stock

Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?

Fusion Pharmaceuticals GAAP EPS of -$0.44 beats by $0.09, revenue of $0.57M beats by $0.46M

Price target decreased to US$16.14

Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-2059, an Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1

Fusion Pharma wins FDA nod to start trials for solid tumor candidate

Fusion Pharmaceuticals Presents Imaging Data from Cold Antibody Sub-Study in the Phase 1 Study of FPI-1434

Fusion Pharmaceuticals Inc. Provides Updates on FPI-1434 and FPI-1966 Clinical Programs

Consensus revenue estimates fall by 84%

Fusion Pharmaceuticals Inc. Announces Executive Changes

Price target decreased to US$18.20

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Fusion Pharmaceuticals Announces Nomination of First Targeted Alpha Therapy Candidate in Collaboration with AstraZeneca to Advance into IND-Enabling Studies for Phase 1 Development

Price target decreased to US$19.00

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Price target decreased to US$21.33

Consensus revenue estimates fall to US$173.7k

Fusion Pharmaceuticals Announces Preliminary Safety and Dosimetry Results from its Single-Dose Portion of the Phase 1 Study of FPI-1434

Fusion Pharma trades higher on early-stage data for cancer therapy

Consensus forecasts updated

We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely

New 90-day low: US$11.25

How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?

Fusion Pharmaceuticals Appoints Philina Lee to Its Board of Directors